MxEA方案治疗难治性急性白血病  

Treatment of refactory acute leukemia with MxEA regiment

作　　者：郭熙哲[1] 潘敬新[1] 张少安[1] 

机构地区：[1]福建医科大学附属第二医院内科,泉州362000

出　　处：《中国临床医学》2004年第1期57-58,共2页Chinese Journal of Clinical Medicine

摘　　要：目的 :探索难治性急性白血病的治疗。方法 :应用米托蒽醌 (Mx) ,10mg·d-1,1d～ 3d ;足叶乙甙 (VP16 ) 10 0mg·d-1,1d～ 5d ;阿糖胞苷 (Ara -c) 2 0 0mg·d-1,1d～ 7d ;7d为一疗程。结果 :2 5例难治性急性白血病 14例CR ,占 5 6 % ,5例PR ,占 2 0 % ,总有效率 76 %。结论 :应用MxEA治疗难治性急性白血病取得较好疗效 ,主要不良反应为骨髓抑制。Objective: To explore the treatment for refractory acute leukemia.Methods:Applied mitoxantrone(10mg·d -1 ,d1～d3),etoposide(VP16, 100mg·d -1 ,1d～5d) and Ara-c(200mg·d -1 ,1d～7d)for 7 days as a treatment phase.Results:In the 25 cases with refractory acute leukemia,14 cases(56%)reached CR,5 cases(20%)reached PR,the total effective rate was 76%.Conclusion: Applied MxEA regiment for refractory acute leukemia can get a good result;the major side effect is marrow inhibition.

关 键 词：MxEA方案 治疗 难治性 急性白血病 米托蒽醌 足叶乙甙 阿糖胞苷 

分 类 号：R733.7[医药卫生—肿瘤]